AAAAAA
Results:
1-15
|
Results: 15
Authors:
Affrime, MB
Banfield, C
Nolop, K
Citation: Mb. Affrime et al., Systemic bioavailability of inhaled corticosteroids: appropriate and comparable methodology, EUR RESP J, 18(1), 2001, pp. 246-246
Authors:
Affrime, MB
Citation: Mb. Affrime, Mometason furoate levels, CHEST, 120(3), 2001, pp. 1035-1035
Authors:
Jen, JF
Cutler, DL
Pai, SM
Batra, VK
Affrime, MB
Zambas, DN
Heft, S
Hajian, G
Citation: Jf. Jen et al., Population pharmacokinetics of temozolomide in cancer patients, PHARM RES, 17(10), 2000, pp. 1284-1289
Authors:
Kosoglou, T
Salfi, M
Lim, JM
Batra, VK
Cayen, MN
Affrime, MB
Citation: T. Kosoglou et al., Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine, BR J CL PH, 50(6), 2000, pp. 581-589
Authors:
Salmun, LM
Herron, JM
Banfield, C
Padhi, D
Lorber, R
Affrime, MB
Citation: Lm. Salmun et al., The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years, CLIN THER, 22(5), 2000, pp. 613-621
Authors:
Pickering, H
Pitcairn, GR
Hirst, PH
Bacon, RE
Newman, SP
Affrime, MB
Marino, M
Citation: H. Pickering et al., Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler, CLIN THER, 22(12), 2000, pp. 1483-1493
Authors:
Affrime, MB
Cuss, F
Padhi, D
Wirth, M
Pai, S
Clement, RP
Lim, J
Kantesaria, B
Alton, K
Cayen, MN
Citation: Mb. Affrime et al., Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers, J CLIN PHAR, 40(11), 2000, pp. 1227-1236
Authors:
Affrime, MB
Kosoglou, T
Thonoor, CM
Flannery, BE
Herron, JM
Citation: Mb. Affrime et al., Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses, CHEST, 118(6), 2000, pp. 1538-1546
Authors:
Gorski, JC
Hall, SD
Becker, P
Affrime, MB
Cutler, DL
Haehner-Daniels, B
Citation: Jc. Gorski et al., In vivo effects of interleukin-10 on human cytochrome P450 activity, CLIN PHARM, 67(1), 2000, pp. 32-43
Authors:
Barbey, JT
Anderson, M
Ciprandi, G
Frew, AJ
Morad, M
Priori, SG
Ongini, E
Affrime, MB
Citation: Jt. Barbey et al., Cardiovascular safety of second-generation antihistamines, AM J RHINOL, 13(3), 1999, pp. 235-243
Authors:
Affrime, MB
Brannan, MD
Lorber, RR
Danzig, MR
Cuss, F
Citation: Mb. Affrime et al., A 3-month evaluation of electrocardiographic effects of loratadine in healthy individuals, ADV THER, 16(4), 1999, pp. 149-157
Authors:
Anjum, S
Swan, SK
Lambrecht, LJ
Radwanski, E
Cutler, DL
Affrime, MB
Halstenson, CE
Citation: S. Anjum et al., Pharmacokinetics of flutamide in patients with renal insufficiency, BR J CL PH, 47(1), 1999, pp. 43-47
Authors:
Andersen, SR
Lambrecht, LJ
Swan, SK
Cutler, DL
Radwanski, E
Affrime, MB
Garaud, JJ
Citation: Sr. Andersen et al., Disposition of recombinant human interleukin-10 in subjects with various degrees of renal function, J CLIN PHAR, 39(10), 1999, pp. 1015-1020
Authors:
Krumpe, P
Lin, CC
Radwanski, E
Cayen, MN
Affrime, MB
Citation: P. Krumpe et al., The penetration of ceftibuten into the respiratory tract, CHEST, 116(2), 1999, pp. 369-374
Authors:
Radwanski, E
Chakraborty, A
Van Wart, S
Huhn, RD
Cutler, DL
Affrime, MB
Jusko, WJ
Citation: E. Radwanski et al., Pharmacokinetics and leukocyte responses of recombinant human interleukin-10, PHARM RES, 15(12), 1998, pp. 1895-1901
Risultati:
1-15
|